<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-125244</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN</dc:title>
<dc:description xml:lang="en">Diabetes increases the risk of both microvascular and macrovascular complications. Although reducing plasma glucose levels to recommended targets decreases the risk of microvascular outcomes, the effects of anti-diabetic drugs on macrovascular complications and cardiovascular death are of concern. In fact, it has been suggested that some anti-diabetic agents could even be harmful for cardiovascular outcomes. In this context, several health care regulatory agencies have established the need for performing clinical trials specifically designed to assess the cardiovascular safety of anti-diabetic drugs. The results of 2 clinical trials have recently been published that provide important information on the cardiovascular safety of dipeptidyl peptidase 4 (DPP-4) inhibitors. The aim of this document was to review the available evidence on the cardiovascular safety of non-insulin anti-diabetic drugs and provide practical recommendations on their use in this context (AU)</dc:description>
<dc:creator>Escobar Cervantes, C</dc:creator>
<dc:creator>Comas Samper, J. M</dc:creator>
<dc:creator>Gasull Molinera, V</dc:creator>
<dc:creator>Prieto, M. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La diabetes mellitus (DM) incrementa el riesgo de presentar complicaciones tanto microvasculares como macrovasculares. Aunque reducir la glucemia hasta los objetivos recomendados reduce el riesgo de complicaciones microvasculares, el efecto de los antidiabéticos sobre las complicaciones macrovasculares y la muerte cardiovascular es motivo de preocupación. Es más, algunos antidiabéticos podrían ser hasta perjudiciales desde el punto de vista de seguridad cardiovascular. En este contexto, las diferentes agencias reguladoras han establecido la necesidad de realizar estudios específicamente diseñados acerca de la seguridad cardiovascular de los antidiabéticos. Recientemente se han publicado los resultados de 2 ensayos clínicos que aportan información relevante acerca de la seguridad cardiovascular de los inhibidores de la dipeptidil peptidasa-4 (DPP-4). El objetivo del presente artículo es revisar la evidencia científica disponible acerca de la seguridad cardiovascular de los diferentes antidiabéticos no insulínicos y realizar unas recomendaciones prácticas sobre su uso en este contexto (AU)</dc:description>
<dc:source>SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.);40(5): 261-273, jul.-ago. 2014.</dc:source>
<dc:identifier>ibc-125244</dc:identifier>
<dc:title xml:lang="es">Seguridad cardiovascular de los antidiabéticos no insulínicos. Posicionamiento científico SEMERGEN</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d1670^s22073</dc:subject>
<dc:subject>^d7182^s22044</dc:subject>
<dc:subject>^d7182^s22002</dc:subject>
<dc:subject>^d2359^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d53366^s22045</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d11756^s22074</dc:subject>
<dc:subject>^d520^s22073</dc:subject>
<dc:subject>^d33150^s22041</dc:subject>
<dc:subject>^d13841^s22073</dc:subject>
<dc:subject>^d30279^s22041</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d33150^s22045</dc:subject>
<dc:subject>^d30279^s22066</dc:subject>
<dc:subject>^d11756^s22045</dc:subject>
<dc:subject>^d53792^s22041</dc:subject>
<dc:type>article</dc:type>
<dc:date>201408</dc:date>
</metadata>
</record>
</ibecs-document>
